Charles River Laboratories International, Inc. (NYSE:CRL) Position Cut by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 1.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 118,098 shares of the medical research company’s stock after selling 1,940 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 0.23% of Charles River Laboratories International worth $31,999,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of CRL. VisionPoint Advisory Group LLC grew its position in Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after purchasing an additional 74 shares during the last quarter. Brown Brothers Harriman & Co. grew its holdings in Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after buying an additional 95 shares in the last quarter. GAMMA Investing LLC acquired a new stake in Charles River Laboratories International in the 4th quarter valued at approximately $62,000. Bruce G. Allen Investments LLC acquired a new stake in Charles River Laboratories International in the 4th quarter valued at approximately $70,000. Finally, Sunbelt Securities Inc. raised its stake in Charles River Laboratories International by 1,072.7% during the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 236 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.9 %

NYSE CRL opened at $199.66 on Monday. The firm’s 50 day moving average price is $216.93 and its two-hundred day moving average price is $231.69. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The stock has a market cap of $10.28 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 1.89 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRLGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 11 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, June 14th. The Goldman Sachs Group assumed coverage on shares of Charles River Laboratories International in a research note on Thursday, June 6th. They set a “buy” rating and a $290.00 target price on the stock. Barclays initiated coverage on shares of Charles River Laboratories International in a research note on Friday, June 28th. They issued an “equal weight” rating and a $230.00 price target for the company. Robert W. Baird lowered their price objective on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Finally, Mizuho initiated coverage on Charles River Laboratories International in a research report on Friday, June 7th. They issued a “neutral” rating and a $235.00 target price for the company. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $254.50.

Check Out Our Latest Report on Charles River Laboratories International

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.